Acumen Pharmaceuticals to Participate in the Stifel 2026 Virtual CNS Forum

Company Overview - Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics targeting toxic soluble amyloid beta oligomers for Alzheimer's disease treatment [3] - The company is headquartered in Newton, Massachusetts [3] Product Development - Acumen is advancing its investigational product candidate, sabirnetug (ACU193), a humanized monoclonal antibody, currently in a Phase 2 clinical trial (ALTITUDE-AD) for early symptomatic Alzheimer's disease patients [3] - The company reported positive results from its Phase 1 trial (INTERCEPT-AD) [3] - Acumen is also exploring a subcutaneous formulation of sabirnetug using Halozyme's ENHANZE® drug delivery technology [3] - Additionally, Acumen is collaborating with JCR Pharmaceuticals to develop an Enhanced Brain Delivery (EBD™) therapy for Alzheimer's disease utilizing a transferrin-receptor-targeting technology [3] Upcoming Events - Management will participate in a fireside chat at the Stifel 2026 Virtual CNS Forum on March 18, 2026, at 11:00 a.m. ET [1] - The live webcast will be accessible under the Investors tab on the company's website and archived for 90 days [2]